At present, there is a lack of evidence from randomized controlled trials on the clinical outcomes of targeted therapy combined with cytotoxic chemotherapy in NSCLC patients after first-line treatment with EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.